Table 1

Demographic and clinical characteristics of chronic ITP patients before and during treatment with thrombopoietic agents

Patient no.Age, ySexSplenectomyPlatelets, ×109/LThrombopoietic agent (time on treatment) at time of blood sampling/collectionPrevious/ongoing non-TPO-R agonist treatment type at time of blood sampling/collection
Pretreatment       
    1 67 Female Yes 29 None 5 mo before IVIg 
    2 66 Female Yes 10 None 4 mo before IVIg 
    3 56 Female Yes 10 None 17 d before IVIg 
    4 70 Male No 22 None Daily low-dose prednisone 
    5 35 Female No 23 None 3 w before IVIg/steroid 
    6 45 Female No 22 None Daily low-dose prednisone 
    7 70 Male No 12 None Daily 60-mg/mL dose prednisone 
    8 17 Female No 31 None 3 mo before anti-D 
    9 46 Female No 26 None 3 mo before anti-D 
    10 61 Female No 36 None Daily low-dose prednisone 
On treatment        
    Same as patient 9 46 Female No 66 AKR-501 (for 4 mo) — 
    Same as patient 10 61 Female No 290 AKR-501 (for 4 mo) Daily low-dose prednisone 
    11 53 Female Yes 49 Romiplostim (for 5 y) — 
    12 52 Male Yes 31 Romiplostim (for 5 y) — 
    13 70 Female No 206 AKR-501 (for 4 mo) — 
    14 80 Female No 140 AKR-501 (for 4 mo) — 
    15 51 Female No 280 Eltrombopag (for 1 y) — 
    16 55 Female No 154 Romiplostim (for 5 y) — 
    17 71 Female Yes 70 Romiplostim (for 5 y) — 
Patient no.Age, ySexSplenectomyPlatelets, ×109/LThrombopoietic agent (time on treatment) at time of blood sampling/collectionPrevious/ongoing non-TPO-R agonist treatment type at time of blood sampling/collection
Pretreatment       
    1 67 Female Yes 29 None 5 mo before IVIg 
    2 66 Female Yes 10 None 4 mo before IVIg 
    3 56 Female Yes 10 None 17 d before IVIg 
    4 70 Male No 22 None Daily low-dose prednisone 
    5 35 Female No 23 None 3 w before IVIg/steroid 
    6 45 Female No 22 None Daily low-dose prednisone 
    7 70 Male No 12 None Daily 60-mg/mL dose prednisone 
    8 17 Female No 31 None 3 mo before anti-D 
    9 46 Female No 26 None 3 mo before anti-D 
    10 61 Female No 36 None Daily low-dose prednisone 
On treatment        
    Same as patient 9 46 Female No 66 AKR-501 (for 4 mo) — 
    Same as patient 10 61 Female No 290 AKR-501 (for 4 mo) Daily low-dose prednisone 
    11 53 Female Yes 49 Romiplostim (for 5 y) — 
    12 52 Male Yes 31 Romiplostim (for 5 y) — 
    13 70 Female No 206 AKR-501 (for 4 mo) — 
    14 80 Female No 140 AKR-501 (for 4 mo) — 
    15 51 Female No 280 Eltrombopag (for 1 y) — 
    16 55 Female No 154 Romiplostim (for 5 y) — 
    17 71 Female Yes 70 Romiplostim (for 5 y) — 

All patients “on treatment” were considered responsive to the thrombopoietic agents, where responsiveness is defined as increasing the platelet count from > 30 × 109/L before starting treatment to a count usually > 50 × 109/L while on treatment. The platelet counts correspond to the patients' counts on the day their blood was analyzed for this study. Thus, although patient 12 had a platelet count of 31 × 109/L when we collected blood for our analysis, the common count for this patient while on treatment was > 50 × 109/L. Of a total of 17 patients, 3 patients were receiving daily low-dose (< 3 mg) immunosuppressive prednisone regimen and one on higher dose (60-mg) at the time of their visit, and all except one (patient 10) was in the pretreatment group.

IVIg indicates intravenous immunoglobulin; and —, none.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal